Researchers have created a new compound that could potentially help mesothelioma patients. Lurbinectedin is a synthetic material that can stop the growth of mesothelioma and other cancers. It works by blocking cytokine transcription in tumor cells. Cytokine transcription is the copying of DNA to allow the passing of the genetic information out of the cell.
Immunotherapy is a blossoming field that is becoming more advanced. Instead of other treatments that kill healthy cells in addition to killing cancerous cells, immunotherapy uses the body’s immune system to fight cancer cells, leaving healthy non-cancerous cells intact. It is a better treatment because it is very effective, more efficient, and is easier on
In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer. It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma. Immunotherapy is a type of
The U.S. Food and Drug Administration recently upgraded its approval of pembrolizumab (Keytruda) for metastatic non-small cell lung cancer, inching it closer to becoming an accepted treatment option for pleural mesothelioma. Pembrolizumab, produced by pharmaceutical giant Merck & Co., also is marketed as Keytruda. The FDA’s announcement last week converted its previous “accelerated” approval in…
The post Using Keytruda for Mesothelioma May Become a Reality appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
The U.S. Food and Drug Administration (FDA) has approved the drug Keytruda for patients with head and neck squamous cell carcinoma (HNSCC).
Recently, the FDA approved Merck immunotherapy drug Keytruda for treatment in non-small cell lung cancer and is bringing hope to mesothelioma patients.
Expanded approved use of new lung cancer drug Opdivo could give malignant pleural mesothelioma patients hope.